Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.

Journal of thrombosis and thrombolysis 20121101

Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.

Thrombosis and haemostasis 20121101

Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.

Thrombosis and haemostasis 20121101

[Concepts in anticoagulant therapy - past, present, and future].

Therapeutische Umschau. Revue therapeutique 20121101

[New anticoagulants - direct factor Xa-inhibitors].

Therapeutische Umschau. Revue therapeutique 20121101

[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].

Therapeutische Umschau. Revue therapeutique 20121101

[Clinical pharmacological aspects of new oral anticoagulants].

Therapeutische Umschau. Revue therapeutique 20121101

How I treat anticoagulated patients undergoing an elective procedure or surgery.

Blood 20121011

Apixaban strengthens its case in atrial fibrillation.

BMJ (Clinical research ed.) 20121010

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.

Neurology 20121002

Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001

Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.

QJM : monthly journal of the Association of Physicians 20121001

Anticoagulants in atrial fibrillation patients with chronic kidney disease.

Nature reviews. Nephrology 20121001

Atrial fibrillation in long term care.

Journal of the American Medical Directors Association 20121001

New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001

New anticoagulants: A concise review.

The journal of trauma and acute care surgery 20121001

[Prophylaxis of thromboembolic events following hip and knee replacement: dabigatran, rivaroxaban or apixaban in comparison to enoxaparin].

Der Unfallchirurg 20121001

Antithrombotic treatment of atrial fibrillation: new insights.

Thrombosis research 20121001

Oral direct factor Xa inhibitors.

Circulation research 20120928

ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF.

Annals of internal medicine 20120918

New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.

Drugs 20120910

Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.

Journal of cardiovascular pharmacology and therapeutics 20120901

Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20120901

Antithrombotic options for atrial fibrillation in 2012.

Cardiovascular & hematological disorders drug targets 20120901

Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.

Coronary artery disease 20120901

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Thrombosis and haemostasis 20120901

[The ARISTOTLE study].

Giornale italiano di cardiologia (2006) 20120901

Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120901

Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation.

Circulation. Cardiovascular quality and outcomes 20120901

The novel oral anticoagulants: an update for the interventional radiologist.

AJR. American journal of roentgenology 20120901

[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].

Therapeutische Umschau. Revue therapeutique 20120901

The promise of novel direct oral anticoagulants.

Best practice & research. Clinical haematology 20120901

Apixaban. After hip or knee replacement: LMWH remains the standard treatment.

Prescrire international 20120901

Apixaban in other situations?

Prescrire international 20120901

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Journal of the American College of Cardiology 20120821

Danger ahead: watch out for indirect comparisons!

Journal of the American College of Cardiology 20120821

ACP Journal Club: review: factor Xa inhibitors reduce DVT more than LMWH in total knee or hip replacement.

Annals of internal medicine 20120821

A new era of antithrombotic therapy in patients with atrial fibrillation.

The American journal of the medical sciences 20120801

Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

Thrombosis research 20120801

Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.

Journal of thrombosis and thrombolysis 20120801

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

The American journal of cardiology 20120801

Novel anticoagulants for non-valvular atrial fibrillation.

Heart, lung & circulation 20120801

Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?

Current clinical pharmacology 20120801

Oral IIa and Xa inhibitors for prevention of stroke in atrial fibrillation: clinical studies and regulatory considerations.

Current clinical pharmacology 20120801

Prevention and treatment of venous thromboembolism and pulmonary embolism: the role of novel oral anticoagulants.

Current clinical pharmacology 20120801

Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors.

Journal of cardiothoracic and vascular anesthesia 20120801

Anticoagulation-related intracranial hemorrhages.

Current atherosclerosis reports 20120801

More light at the end of the tunnel - apixaban in atrial fibrillation.

Expert opinion on investigational drugs 20120801

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

International angiology : a journal of the International Union of Angiology 20120801

Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20120801

Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.

Minerva cardioangiologica 20120801

The new oral anticoagulants: a challenge for hospital formularies.

Hospital practice (1995) 20120801

Renal profiles of anticoagulants.

Journal of clinical pharmacology 20120701

Apixaban: a novel oral inhibitor of factor Xa.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120701

Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.

Circulation. Cardiovascular quality and outcomes 20120701

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Circulation. Cardiovascular quality and outcomes 20120701

Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.

Chinese medical journal 20120701

Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

Drugs 20120618

New oral anticoagulants for venous thromboembolism: focus on factor Xa and thrombin inhibitors.

Current drug discovery technologies 20120601

Apixaban: a new player in the anticoagulant class.

Current drug targets 20120601

Novel oral anticoagulants after acute coronary syndromes.

Cardiovascular drugs and therapy 20120601

Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients.

Thrombosis and haemostasis 20120601

New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.

Journal of internal medicine 20120601

Novel antithrombotic agents for atrial fibrillation.

Pharmacology & therapeutics 20120601

Long-term benefits of preventing venous thromboembolic events.

Current medical research and opinion 20120601

[Pharmacology of the new oral anticoagulants].

Herz 20120601

[Role of the new oral anticoagulants in comparison to vitamin K antagonists in practice].

Herz 20120601

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.

The Lancet. Neurology 20120601

Reducing the risk of recurrent stroke in patients with AF.

The Lancet. Neurology 20120601

Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.

Critical pathways in cardiology 20120601

A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.

Critical pathways in cardiology 20120601

The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.

Expert opinion on therapeutic patents 20120601

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Advances in therapy 20120601

Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs.

Discovery medicine 20120601

Anticoagulant therapy for patients with ischaemic stroke.

Nature reviews. Neurology 20120508

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Drugs 20120507

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.

Thrombosis and haemostasis 20120501

A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.

Journal of thrombosis and haemostasis : JTH 20120501

Reversal of antithrombotic agents.

American journal of hematology 20120501

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

American journal of hematology 20120501

Implementing the new oral anticoagulants into the hospital formulary.

American journal of hematology 20120501

Novel oral anticoagulants--key messages for the angiologist.

VASA. Zeitschrift fur Gefasskrankheiten 20120501

Newer oral anticoagulant agents: a new era in medicine.

Current cardiology reviews 20120501

Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.

Archives of internal medicine 20120423

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.

Journal of the American College of Cardiology 20120417

Novel anticoagulants for atrial fibrillation: a critical appraisal.

Angiology 20120401

New oral anticoagulants for atrial fibrillation: a review of clinical trials.

Clinical therapeutics 20120401

[Novel oral anticoagulants and their use in the perioperative setting].

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 20120401

Practical use of apixaban in the prevention of venous thromboembolism after total knee or hip replacement.

Drugs of today (Barcelona, Spain : 1998) 20120401

Preventing venous thromboembolic events after total hip arthroplasty: new developments in clinical practice.

Hospital practice (1995) 20120401

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Thrombosis and haemostasis 20120301

Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.

Thrombosis research 20120301

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.

The Lancet. Neurology 20120301

Critique of apixaban versus warfarin in patients with atrial fibrillation.

Stroke 20120301

What's the 'go to' anticoagulant for stroke prevention in atrial fibrillation?

Thrombosis and haemostasis 20120301

New directions in anticoagulation.

The American journal of medicine 20120301

Prevention of stroke in atrial fibrillation: cautious optimism.

The Lancet. Neurology 20120301

A new generation of oral direct anticoagulants.

Arteriosclerosis, thrombosis, and vascular biology 20120301

Apixaban: an oral direct factor-xa inhibitor.

Advances in therapy 20120301

Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20120301

Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.

Expert review of cardiovascular therapy 20120301

The efficacy and safety of postoperative autologous transfusion of filtered shed blood and anticoagulant prophylaxis in total knee arthroplasty patients.

Knee surgery & related research 20120301

Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.

Nature reviews. Cardiology 20120227

Rational approaches to improving selectivity in drug design.

Journal of medicinal chemistry 20120223

Apixaban versus enoxaparin in medically ill patients.

The New England journal of medicine 20120223

Oral factor Xa inhibitors for the long-term management of ACS.

Nature reviews. Cardiology 20120221

Anticoagulant management in the cardiovascular setting.

Fundamental & clinical pharmacology 20120201

Rivaroxaban for the prevention and treatment of venous thromboembolism.

Fundamental & clinical pharmacology 20120201

New anticoagulants for the prevention of stroke in atrial fibrillation.

Fundamental & clinical pharmacology 20120201

Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation.

Journal of cardiovascular medicine (Hagerstown, Md.) 20120201

The year in Cardiothoracic and Vascular Anesthesia: selected highlights from 2011.

Journal of cardiothoracic and vascular anesthesia 20120201

The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?

International journal of stroke : official journal of the International Stroke Society 20120201

Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.

Expert review of neurotherapeutics 20120201

Apixaban for the prevention of stroke in atrial fibrillation.

Expert review of cardiovascular therapy 20120201

Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis.

Seminars in thrombosis and hemostasis 20120201

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Chest 20120201

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

The Journal of bone and joint surgery. British volume 20120201

Apixaban reduced stroke and systemic embolism compared with warfarin in atrial fibrillation.

Annals of internal medicine 20120117

Apixaban versus warfarin in atrial fibrillation.

The New England journal of medicine 20120105

Apixaban versus warfarin in atrial fibrillation.

The New England journal of medicine 20120105

Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.

Journal of neurology 20120101

[Anticoagulation in atrial fibrillation: a new era has begun].

Hamostaseologie 20120101

[Anticoagulation for atrial fibrillation : the future has begun].

Der Internist 20120101

[Apixaban: pharmacology and action profile].

Deutsche medizinische Wochenschrift (1946) 20120101

New frontiers for stroke prevention in atrial fibrillation.

Cerebrovascular diseases (Basel, Switzerland) 20120101

ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?

Cardiology journal 20120101

Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.

Postgraduate medicine 20120101

New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.

Vascular health and risk management 20120101

I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?

DukeMedicine healthnews 20120101

Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy.

Cardiology research and practice 20120101

A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?

Polskie Archiwum Medycyny Wewnetrznej 20120101

Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.

Connecticut medicine 20120101

Improving prevention and treatment of venous thromboembolism: clinical trial results.

Journal of medical economics 20120101

Stroke Prevention in Atrial Fibrillation: Where are We Now?

Clinical Medicine Insights. Cardiology 20120101

Cost considerations in the management of atrial fibrillation - impact of dronedarone.

ClinicoEconomics and outcomes research : CEOR 20120101

Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.

The Canadian journal of cardiology 20120101

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.

Journal of medical economics 20120101

Current status of new anticoagulants in the management of venous thromboembolism.

Advances in hematology 20120101

Costs and clinical consequences of suboptimal atrial fibrillation management.

ClinicoEconomics and outcomes research : CEOR 20120101

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery.

Therapeutics and clinical risk management 20120101

Oral anticoagulants. New oral anticoagulants for atrial fibrillation: the factor Xa inhibitors rivaroxaban and apixaban.

Reviews in cardiovascular medicine 20120101

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients.

ClinicoEconomics and outcomes research : CEOR 20120101

Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants.

Journal of blood medicine 20120101

Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease.

Thrombosis 20120101

[New antithrombotic drugs].

Duodecim; laaketieteellinen aikakauskirja 20120101

Advances in the diagnosis and treatment of acute pulmonary embolism.

F1000 medicine reports 20120101

Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011.

Open medicine : a peer-reviewed, independent, open-access journal 20120101

Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study.

BMJ (Clinical research ed.) 20120101

Non-pharmacological therapy for atrial fibrillation: managing the left atrial appendage.

Cardiology research and practice 20120101

Newer anticoagulants for the prevention of venous thromboembolism.

The National medical journal of India 20120101

Emerging anticoagulants.

Current medicinal chemistry 20120101

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.

BMJ (Clinical research ed.) 20120101

Health technology assessment and its role in the future development of the Indian healthcare sector.

Perspectives in clinical research 20120101

[Apixaban].

Hamostaseologie 20120101

[New anticoagulants: dabigatran, rivaroxaban and apixaban].

Gaceta medica de Mexico 20120101

An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.

Core evidence 20120101

Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.

Current medicinal chemistry 20120101

Safety and efficacy of apixaban in the treatment of atrial fibrillation.

Clinical Medicine Insights. Cardiology 20120101

Perioperative stroke risk in nonvascular surgery.

Cerebrovascular diseases (Basel, Switzerland) 20120101

Vitamin K antagonists. Ready to be replaced?

Hamostaseologie 20120101

Understanding the new emerging oral anticoagulants for venous thromboembolism prophylaxis.

Orthopedic nursing 20120101

Rivaroxaban in atrial fibrillation.

Vascular health and risk management 20120101

Prevention of stroke and systemic embolization in atrial fibrillation: a Canadian perspective.

Polskie Archiwum Medycyny Wewnetrznej 20120101

Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban.

Thrombosis 20120101

[New oral anticoagulants for atrial fibrillation: a neurologist's view].

Nederlands tijdschrift voor geneeskunde 20120101

Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?

Thrombosis 20120101

Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.

BMJ open 20120101

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation.

PloS one 20120101

Left atrial appendage exclusion for stroke prevention in atrial fibrillation.

Cardiology research and practice 20120101

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

The New England journal of medicine 20111208

Antiplatelet agents and anticoagulants for hypertension.

The Cochrane database of systematic reviews 20111207

In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding.

Evidence-based medicine 20111201

[Thrombosis prophylaxis in surgery. What is the evidence?].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20111201

Antithrombotic therapy in nonvalvular atrial fibrillation: a narrative review.

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20111201

Clinical trials update from the European Society of Cardiology Meeting 2011: ARISTOTLE, SMART-AV: QLV substudy, SHIFT: echocardiography and quality of life substudies, European CRT Survey, and Basic Science Update.

European journal of heart failure 20111201

[Pharmacologic heterogeneity of new anticoagulants].

Journal des maladies vasculaires 20111201

[ADOPT study. Longer thrombosis prevention in internal medicine patients has no advantage].

MMW Fortschritte der Medizin 20111201

Antithrombotic therapy for secondary stroke prevention.

Continuum (Minneapolis, Minn.) 20111201

Apixaban after acute coronary syndrome.

The New England journal of medicine 20111110

External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?

Journal of thrombosis and haemostasis : JTH 20111101

Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.

Current medical research and opinion 20111101

[New anticoagulants. Characteristics, monitoring and management of bleeding].

Medizinische Klinik, Intensivmedizin und Notfallmedizin 20111101

[Current status and future of anti-Xa inhibitors].

Rinsho shinkeigaku = Clinical neurology 20111101

[New anticoagulants].

La Revue du praticien 20111101

Apixaban: first global approval.

Drugs 20111022

Trial watch: apixaban beats warfarin in stroke trial.

Nature reviews. Drug discovery 20111014

Apixaban in acute coronary syndromes.

Cardiovascular therapeutics 20111001

Inhibitors of propagation of coagulation: factors V and X.

British journal of clinical pharmacology 20111001

Anticoagulating obese patients in the modern era.

British journal of haematology 20111001

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.

European heart journal 20111001

New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.

Pharmacotherapy 20111001

The role of apixaban for venous and arterial thromboembolic disease.

The Annals of pharmacotherapy 20111001

Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.

Orthopedics 20111001

The new oral anticoagulants.

Clinical medicine (London, England) 20111001

Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.

Hospital practice (1995) 20111001

[New antithrombotic drugs for the treatment of venous thromboembolism].

Revue des maladies respiratoires 20111001

CSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions.

Journal of chemical information and modeling 20110926

[Atrial fibrillation: what the GP needs to know].

MMW Fortschritte der Medizin 20110922

[Modern risk assessment and stroke prevention in atrial fibrillation].

Praxis 20110921

A new era for anticoagulation in atrial fibrillation.

The New England journal of medicine 20110915

Apixaban versus warfarin in patients with atrial fibrillation.

The New England journal of medicine 20110915

[Anticoagulation in atrial fibrillation. Standard in stroke prevention is eliminated].

MMW Fortschritte der Medizin 20110915

Atrial fibrillation: ARISTOTLE reveals superiority of apixaban over warfarin in patients with atrial fibrillation.

Nature reviews. Cardiology 20110913

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

European journal of drug metabolism and pharmacokinetics 20110901

Emerging options in the treatment of deep vein thrombosis and pulmonary embolism.

Blood reviews 20110901

Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.

Journal of thrombosis and haemostasis : JTH 20110901

Update on anti-coagulation in atrial fibrillation.

QJM : monthly journal of the Association of Physicians 20110901

[The AVERROES study].

Giornale italiano di cardiologia (2006) 20110901

[Thromboembolic prophylaxis 2011: is warfarin on the wane?].

Giornale italiano di cardiologia (2006) 20110901

Apixaban with antiplatelet therapy after acute coronary syndrome.

The New England journal of medicine 20110825

New antithrombotic drugs and European approval processes.

Lancet (London, England) 20110820

[The new Anticoagulants - Relevant Facts for the GP].

Praxis 20110810

[Apixaban for prevention of thrombosis in hip replacement].

Praxis 20110810

['Xa-tra-xa': opportunities and open questions about new anticoagulants].

Praxis 20110810

Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma.

Journal of enzyme inhibition and medicinal chemistry 20110801

Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.

European heart journal 20110801

Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.

Journal of thrombosis and thrombolysis 20110801

New anticoagulants for prevention of stroke in patients with atrial fibrillation.

Journal of cardiovascular electrophysiology 20110801

Apixaban in atrial fibrillation: from bleeding cows to 21st century medicinal chemistry.

Stroke 20110801

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20110801

Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.

American journal of therapeutics 20110701

Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.

Current opinion in cardiology 20110701

Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.

Journal of thrombosis and haemostasis : JTH 20110701

[New anticoagulants in the prevention and treatment of venous thromboembolism].

Orvosi hetilap 20110619

Apixaban in patients with atrial fibrillation.

The New England journal of medicine 20110616

Apixaban in patients with atrial fibrillation.

The New England journal of medicine 20110616

The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.

International journal of stroke : official journal of the International Stroke Society 20110601

[New oral anticoagulants for treatment of venous thromboembolism].

Deutsche medizinische Wochenschrift (1946) 20110601

What's new in stroke? The top 10 studies of 2009-2011: part II.

Polskie Archiwum Medycyny Wewnetrznej 20110601

ACP journal club. Apixaban reduced VTE and did not increase major bleeding compared with enoxaparin in hip replacement.

Annals of internal medicine 20110517

Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer?

Current vascular pharmacology 20110501

Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?

Reviews on recent clinical trials 20110501

Modelling and simulation as research tools in paediatric drug development.

European journal of clinical pharmacology 20110501

Laboratory assessment of new anticoagulants.

Clinical chemistry and laboratory medicine 20110501

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.

Journal of thrombosis and thrombolysis 20110501

Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap?

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20110501

[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].

Medecine sciences : M/S 20110501

[The new anticoagulants].

Harefuah 20110501

ACP Journal Club. Apixaban reduced stroke and systemic embolism compared with aspirin in adults with AF for whom VKA therapy was unsuitable.

Annals of internal medicine 20110419

[Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].

MMW Fortschritte der Medizin 20110414

The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.

Pharmacology & therapeutics 20110401

What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?

Thrombosis and haemostasis 20110401

New oral anticoagulants.

Journal of thrombosis and thrombolysis 20110401

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Journal of thrombosis and thrombolysis 20110401

Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

Expert opinion on investigational drugs 20110401

Arrhythmias: apixaban triumphs over aspirin for stroke prevention in patients with atrial fibrillation.

Nature reviews. Cardiology 20110401

Apixaban vs. enoxaparin after hip replacement.

The New England journal of medicine 20110324

Apixaban in patients with atrial fibrillation.

The New England journal of medicine 20110303

Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery.

Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 20110301

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate.

British journal of haematology 20110301

Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.

Expert opinion on pharmacotherapy 20110301

Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.

Thrombosis and haemostasis 20110201

Tissue distribution and elimination of [14C]apixaban in rats.

Drug metabolism and disposition: the biological fate of chemicals 20110201

New anticoagulant agents in acute coronary syndromes.

Heart (British Cardiac Society) 20110201

Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism.

Phlebology 20110201

[New oral anticoagulants in atrial fibrillation].

Der Nervenarzt 20110201

New anticoagulants: pharmacology and clinical studies.

Wiener medizinische Wochenschrift (1946) 20110201

New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.

The American journal of managed care 20110201

Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.

Thrombosis and haemostasis 20110101

Factor Xa and thrombin as targets for new oral anticoagulants.

Thrombosis research 20110101

Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.

Annual review of medicine 20110101

New oral anticoagulants: should they replace heparins and warfarin?

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20110101

[Summary of the article: Lassen MR, Gallus A, Borris LC et al. Apixaban vs enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med, 2010; 363: 2487-2498].

Kardiologia polska 20110101

Heparin-induced thrombocytopenia in the ICU: an overview.

Critical care (London, England) 20110101

The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation.

Vascular health and risk management 20110101

New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery.

Instructional course lectures 20110101

[Drug prevention of pulmonary embolism in orthopedic practice: traditional and novel approaches].

Kardiologiia 20110101

Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study-.

Circulation journal : official journal of the Japanese Circulation Society 20110101

Thrombin inhibitor or factor xa inhibitor? -Opening of a New Era of antithrombotic management-.

Circulation journal : official journal of the Japanese Circulation Society 20110101

Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective.

Thrombosis journal 20110101

Antithrombotic medication for cardioembolic stroke prevention.

Stroke research and treatment 20110101

Management of patients with atrial fibrillation: specific considerations for the old age.

Cardiology research and practice 20110101

Evaluation of marine brown algae and sponges from Brazil as anticoagulant and antiplatelet products.

Marine drugs 20110101

Tissue factor, blood coagulation, and beyond: an overview.

International journal of inflammation 20110101

Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.

Advances in surgery 20110101

[The new oral anticoagulants in surgery].

Revista medica del Instituto Mexicano del Seguro Social 20110101

European Society of Cardiology congress 2011.

Cardiovascular journal of Africa 20110101

Role of factor xa inhibitors in cancer-associated thrombosis: any new data?

Advances in hematology 20110101

Emerging therapies for acute coronary syndromes.

Frontiers in pharmacology 20110101

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.

BMJ (Clinical research ed.) 20110101

Venous thromboembolism: classification, risk factors, diagnosis, and management.

ISRN hematology 20110101

Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants.

Thrombosis journal 20110101

Gene-drug interaction in stroke.

Stroke research and treatment 20110101

Cardiac arrest caused by multiple recurrent pulmonary embolism.

Case reports in medicine 20110101

The case for an elderly targeted stroke management.

Frontiers in neurology 20110101

Deep vein thrombosis: a clinical review.

Journal of blood medicine 20110101

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

The New England journal of medicine 20101223

Therapeutic potential of oral factor Xa inhibitors.

The New England journal of medicine 20101223

Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.

Journal of the American College of Cardiology 20101214

[New oral anticoagulants: better than vitamin K antagonists?].

Der Internist 20101201

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

Thrombosis and haemostasis 20101201

New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.

Clinics in chest medicine 20101201

Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.

Thrombosis and haemostasis 20101101

Intracerebral hemorrhage: Pick your poison.

Cleveland Clinic journal of medicine 20101101

[Novel anticoagulants for stroke prevention in atrial fibrillation].

Deutsche medizinische Wochenschrift (1946) 20101101

[New oral anticoagulants from the perspective of trauma surgery].

Der Unfallchirurg 20101101

New options for stroke prevention in atrial fibrillation.

The American journal of managed care 20101101

New antithrombotics for atrial fibrillation.

Cardiovascular therapeutics 20101001

Emerging antithrombotic agents: what does the intensivist need to know?

Current opinion in critical care 20101001

Factor Xa inhibitors: next-generation antithrombotic agents.

Journal of medicinal chemistry 20100909

Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.

Journal of clinical pharmacology 20100901

New antithrombotic agents--insights from clinical trials.

Nature reviews. Cardiology 20100901

Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.

Clinical pharmacology and therapeutics 20100901

Novel oral anticoagulants: implications in the perioperative setting.

Anesthesiology 20100901

Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.

Journal of cardiovascular pharmacology 20100801

Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.

Thrombosis and haemostasis 20100801

Treatment of thromboembolism in cancer patients.

Expert opinion on pharmacotherapy 20100801

[Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100801

Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.

Current opinion in cardiology 20100701

[A new deal with new anticoagulants?].

Journal des maladies vasculaires 20100601

Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis.

Journal of cardiovascular pharmacology 20100601

Old versus new anticoagulants: focus on pharmacology.

Recent patents on cardiovascular drug discovery 20100601

Drug and dietary interactions of the new and emerging oral anticoagulants.

International journal of clinical practice 20100601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100601

Novel oral anticoagulants. Part II: direct thrombin inhibitors.

Expert review of hematology 20100601

Emerging anticoagulants for venous thromboembolism prevention.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100515

Primary prevention of venous thromboembolism in medical and surgical oncology patients.

British journal of cancer 20100413

Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?

Lupus 20100401

VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.

Thrombosis research 20100401

Potential of new anticoagulants in patients with cancer.

Thrombosis research 20100401

Health trends.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20100401

Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors).

Expert review of hematology 20100401

Apixaban to prevent venous thromboembolism after knee replacement.

Lancet (London, England) 20100306

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Lancet (London, England) 20100306

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.

Drug metabolism and disposition: the biological fate of chemicals 20100301

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.

Thrombosis and haemostasis 20100301

Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.

The Lancet. Neurology 20100301

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

American heart journal 20100301

Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.

American heart journal 20100301

[Pulmonary circulation: contributions of the year 2009].

Archivos de bronconeumologia 20100301

Recent advances in the management of venous thromboembolism.

The Korean journal of hematology 20100301

Phenyltriazolinones as potent factor Xa inhibitors.

Bioorganic & medicinal chemistry letters 20100215

New oral anticoagulants: a practical guide for clinicians.

Journal of thrombosis and thrombolysis 20100201

The new oral anticoagulants.

Blood 20100107

Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits.

Journal of thrombosis and thrombolysis 20100101

Apixaban: an emerging oral factor Xa inhibitor.

Journal of thrombosis and thrombolysis 20100101

New oral anticoagulants in development: potential for improved safety profiles.

Reviews in neurological diseases 20100101

Forecasting drug utilization and expenditure in a metropolitan health region.

BMC health services research 20100101

New options with dabigatran etexilate in anticoagulant therapy.

Vascular health and risk management 20100101

New anticoagulants for the prevention of venous thromboembolism.

Drug design, development and therapy 20100101

Novel anticoagulant therapy: principle and practice.

Methods in molecular biology (Clifton, N.J.) 20100101

Prevention strategies for cardioembolic stroke: present and future perspectives.

The open neurology journal 20100101

New anticoagulants for the prevention of thromboembolism.

Current pharmaceutical design 20100101

Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.

Current pharmaceutical design 20100101

Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice.

F1000 medicine reports 20100101

Newer antithrombotic drugs.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 20100101

Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery.

Thrombosis 20100101

New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty.

Thrombosis 20100101

Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations.

Journal of blood medicine 20100101

Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review.

Internal and emergency medicine 20091201

Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?

Discovery medicine 20091201

Apixaban or enoxaparin for thromboprophylaxis.

The New England journal of medicine 20091119

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20091101

New antithrombotic drugs: potential for use in oncology.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091010

New anticoagulants and regional anesthesia.

Current opinion in anaesthesiology 20091001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20091001

Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change.

Current opinion in hematology 20090901

[New developments in antithrombotic care].

Revue medicale de Bruxelles 20090901

Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

The New England journal of medicine 20090806

Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.

Drug metabolism and disposition: the biological fate of chemicals 20090801

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.

Journal of thrombosis and haemostasis : JTH 20090801

Recent developments in the use of oral anticoagulants.

Expert opinion on pharmacotherapy 20090801

Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.

Journal of cardiovascular medicine (Hagerstown, Md.) 20090801

Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.

Annals of surgery 20090801

Factor Xa inhibitors--new anticoagulants for secondary haemostasis.

Hamostaseologie 20090801

New anticoagulants: focus on venous thromboembolism.

Current vascular pharmacology 20090701

New anticoagulants for atrial fibrillation.

Seminars in thrombosis and hemostasis 20090701

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

Circulation 20090609

3-(3-Chloro-anilino)-1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-1-one.

Acta crystallographica. Section E, Structure reports online 20090601

Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.

European journal of haematology 20090501

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.

Bioorganic & medicinal chemistry letters 20090415

Sulfation of o-demethyl apixaban: enzyme identification and species comparison.

Drug metabolism and disposition: the biological fate of chemicals 20090401

Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.

Thrombosis and haemostasis 20090401

[Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].

Vnitrni lekarstvi 20090301

The novel anticoagulants: entering a new era.

Swiss medical weekly 20090207

New anticoagulants - towards the development of an 'ideal' anticoagulant.

VASA. Zeitschrift fur Gefasskrankheiten 20090201

Laboratory monitoring of anticoagulation: where do we stand?

Seminars in thrombosis and hemostasis 20090201

Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.

Bioorganic & medicinal chemistry letters 20090115

Apixaban metabolism and pharmacokinetics after oral administration to humans.

Drug metabolism and disposition: the biological fate of chemicals 20090101

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

Clinical pharmacokinetics 20090101

In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.

Orthopedics 20090101

New oral anticoagulants: not quite there yet.

Polskie Archiwum Medycyny Wewnetrznej 20090101

Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke.

Cerebrovascular diseases (Basel, Switzerland) 20090101

Use of anticoagulants in elderly patients: practical recommendations.

Clinical interventions in aging 20090101

Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Vascular health and risk management 20090101

The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Vascular health and risk management 20090101

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict.

Expert opinion on investigational drugs 20081201

Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.

Vascular health and risk management 20081201

[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].

Medicina clinica 20081101

Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits.

Journal of thrombosis and haemostasis : JTH 20081001

Apixaban, an oral, direct inhibitor of activated Factor Xa.

Current opinion in investigational drugs (London, England : 2000) 20080901

New developments in anticoagulation for atrial fibrillation.

Current treatment options in cardiovascular medicine 20080901

Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.

Journal of thrombosis and haemostasis : JTH 20080801

New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.

Vascular health and risk management 20080801

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.

Journal of thrombosis and haemostasis : JTH 20080501

Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.

Bioorganic & medicinal chemistry letters 20080501

New anticoagulants for treatment of venous thromboembolism.

Arteriosclerosis, thrombosis, and vascular biology 20080301

Update on atrial fibrillation: part I.

Clinical cardiology 20080201

[New anticoagulants].

Hamostaseologie 20080201

Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.

Seminars in thrombosis and hemostasis 20080201

The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.

Seminars in thrombosis and hemostasis 20080201

New oral anticoagulants in atrial fibrillation.

European heart journal 20080101

The top 4 advances in antithrombotic care in the last year.

Thrombosis research 20080101

Brave new world: the current and future use of novel anticoagulants.

Thrombosis research 20080101

Gateways to clinical trials. July-August 2008.

Methods and findings in experimental and clinical pharmacology 20080101

Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

Journal of autoimmune diseases 20080101

New issues in oral anticoagulants.

Hematology. American Society of Hematology. Education Program 20080101

Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review.

Pathophysiology of haemostasis and thrombosis 20080101

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

Journal of thrombosis and haemostasis : JTH 20071201

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.

Journal of medicinal chemistry 20071101

SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.

Bioorganic & medicinal chemistry letters 20070815

Beyond unfractionated heparin and warfarin: current and future advances.

Circulation 20070731

Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.

Arteriosclerosis, thrombosis, and vascular biology 20070601

Investigational treatments of venous thromboembolism.

Expert opinion on investigational drugs 20070401

Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.

Annals of medicine 20070101

Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery.

Drugs 20060101